Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; and a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IMMU
CUSIP45290710
Phone973-605-8200
Debt
Debt-to-Equity Ratio2.81
Current Ratio3.94
Quick Ratio3.94
Price-To-Earnings
Trailing P/E Ratio-25.93
Forward P/E Ratio-16.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.09 million
Price / Sales1,137.33
Cash FlowN/A
Price / CashN/A
Book Value($0.54) per share
Price / Book-38.89
Profitability
EPS (Most Recent Fiscal Year)($0.81)
Net Income$-153,200,000.00
Net Margins-8,708.96%
Return on EquityN/A
Return on Assets-47.04%
Miscellaneous
Employees138
Outstanding Shares167,350,000
Market Cap$3.95 billion
Immunomedics (NASDAQ:IMMU) Frequently Asked Questions
What is Immunomedics' stock symbol?
Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."
How were Immunomedics' earnings last quarter?
Immunomedics, Inc. (NASDAQ:IMMU) posted its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.06. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to analysts' expectations of $4.27 million. The firm's revenue for the quarter was down 61.5% on a year-over-year basis. View Immunomedics' Earnings History.
When is Immunomedics' next earnings date?
What price target have analysts set for IMMU?
3 brokers have issued 1-year price objectives for Immunomedics' stock. Their forecasts range from $27.00 to $53.00. On average, they expect Immunomedics' stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 76.2% from the stock's current price. View Analyst Price Targets for Immunomedics.
What is the consensus analysts' recommendation for Immunomedics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.
Are investors shorting Immunomedics?
Immunomedics saw a drop in short interest in July. As of July 31st, there was short interest totalling 16,963,631 shares, a drop of 15.9% from the July 13th total of 20,165,241 shares. Based on an average daily trading volume, of 1,942,013 shares, the short-interest ratio is currently 8.7 days. Currently, 10.8% of the shares of the stock are sold short. View Immunomedics' Current Options Chain.
Who are some of Immunomedics' key competitors?
Some companies that are related to Immunomedics include IPSEN S A/S (IPSEY), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML) and ImmuCell (ICCC).
Who are Immunomedics' key executives?
Immunomedics' management team includes the folowing people:
- Mr. Michael R. Garone, CFO, Principal Accounting Officer & VP of Fin. (Age 59)
- Mr. Michael F. Pehl, Pres, CEO & Director (Age 53)
- Ms. Phyllis Parker, Director of Admin.
- Dr. Chau Cheng, Sr. Director of Investor Relations & Corp. Sec.
- Dr. William A. Wegener, Chief Medical Officer
Has Immunomedics been receiving favorable news coverage?
News headlines about IMMU stock have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immunomedics earned a news impact score of 0.11 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 48.94 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Immunomedics.
Who are Immunomedics' major shareholders?
Immunomedics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.71%), FMR LLC (5.08%), SEATTLE GENETICS INC (4.90%), Orbimed Advisors LLC (2.95%), Acuta Capital Partners LLC (2.84%) and Millennium Management LLC (2.24%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.
Which major investors are selling Immunomedics stock?
IMMU stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Orbimed Advisors LLC, DAFNA Capital Management LLC, First Trust Advisors LP, Wells Fargo & Company MN, Alps Advisors Inc., PNC Financial Services Group Inc. and EAM Global Investors LLC. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison, Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.
Which major investors are buying Immunomedics stock?
IMMU stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management LLC, BlackRock Inc., American Century Companies Inc., Voya Investment Management LLC, Janus Henderson Group PLC, Millennium Management LLC, FMR LLC and Menora Mivtachim Holdings LTD.. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.
How do I buy shares of Immunomedics?
Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immunomedics' stock price today?
One share of IMMU stock can currently be purchased for approximately $21.00.
How big of a company is Immunomedics?
Immunomedics has a market capitalization of $3.95 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Immunomedics employs 138 workers across the globe.
How can I contact Immunomedics?
Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]
MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
